Despite of the high prevalence, pathogenesis of female sexual dysfunction (FSD) is still poorly understood. A consecutive series of sexually active women underwent a health investigation and completed a questionnaire on FSD. Metabolic syndrome (MS) was defined according to the International Diabetes Federation definition. A total of 538 women with a mean age of 44 years (range: 30-69) was analysed. The premenopausal group comprised 329 women (61.2%) with a mean age of 38.5 years; the postmenopausal cohort contained 209 women (38.8%) with a mean age of 52.7 years. In the total cohort (n ¼ 538) MS was present in 17.6%, 8.5% in the premenopausal group and 32.6% in the postmenopausal women. In premenopausal women, the MS was an independent risk factor for impaired sexual desire (P ¼ 0.03) with an age-adjusted odds ratio of 3.3 (95% confidence interval: 1.5-7.3). In premenopausal female sexual life, the MS represents an independent role via its correlation to impaired desire.
Introduction
Female sexual dysfunction (FSD) is a common and multidimensional disorder related to a broad variety of biological, psychological and interpersonal determinants. [1] [2] [3] [4] [5] [6] [7] Despite the high prevalence of FSD, detailed knowledge on risk factors and therapeutic options is scant.
Among the multitude of factors influencing sexual integrity in women, different aspects of lifestyle are considered to play a significant role in the genesis of FSD. 8, 9 Esposito et al. 10 recently reported on an independent impact of the metabolic syndrome (MS) for the genesis of FSD in premenopausal women.
The MS represents a highly prevalent medical constellation triggered by abdominal obesity promoting resistance to the effects of insulin on peripheral glucose and fatty acid utilization. Insulin resistance, the associated hyperinsulinaemia, hyperglycaemia and adipocyte cytokines may lead to an abnormal lipid profile and hypertension. The resulting vascular inflammation and endothelial dysfunction are the promoting key factors in the development of atherosclerosis. 11, 12 Among the broad variety of possible risk factors for FSD, one may be via vascular dysfunction due to the MS resulting in impaired tissue oxygenation and subsequently to structural and functional damage of the female genital tract.
To investigate the impact of the MS on FSD in premenopausal and postmenopausal women, we analysed a previously reported cohort of women participating in a health-screening project. 4 
Patients and methods

Study cohort
A consecutive cohort of women participating in a voluntary health examination free of charge in the area of Vienna was analysed. Institutional Review Board approval was obtained and all study participants gave informed consent. Prevalence and major risk factors for FSD within the entire cohort and the FSD-questionnaire have been published previously. 4 For the current analysis, all women younger than 30 or older than 69 years and those having endocrinological/gynaecological diseases were excluded. Sexually inactive women, as stated in the questionnaire ('no activity in the last 4 weeks') were excluded as well, as specific reasons for individual inactivity were not indicated.
Health investigation
During the health examination, a standardized medical status including the following parameters was obtained: age, weight, height, waist circumference, blood pressure (BP); nicotine abuse; blood laboratory study with low-and high-density lipoprotein counts, total cholesterol, triglycerides and fasting serum glucose.
Metabolic syndrome
To calculate the prevalence of MS, the International Diabetes Federation consensus definition was applied, as it is the most recent one with specific cutoff values for female Europids. 13 The International Diabetes Federation definition comprises a waist circumference X80 cm plus any two of the following factors: 
Parameters
Total cholesterol, triglycerides and high-density lipoprotein were quantified using Hitachi 717 by Roche (BM) with serum of fasting patients between 0800 and 1000 hours. Low-density lipoprotein was calculated according to the Friedwald's formula.
For systolic and diastolic BP determination, three measurements were obtained for each individual, (1) by the study nurse before medical examination, (2) by the general practitioner during medical examination and (3) by the study nurse after medical examination each time after the patient had been sitting for 5 min. Mean values of these three measurements were used for all analyses.
Questionnaire
The study was initiated in 2000, at that time no validated German FSD questionnaire was available. We therefore designed a 23-item FSD questionnaire primarily based on the report of the International Consensus Development Conference on FSD. 13 This questionnaire has been published previously. 4 For the current analyses the following representative questions were chosen and cutoff definitions of FSD sexually active women were applied. All answers referred to the preceding 4 weeks: Table 1) . In premenopausal women, the highest prevalence was seen for desire disorders (38.5%), followed by low sexual frequency (31.2%) and orgasms disorders (22.2%) ( Table 2 ). In postmenopausal women, low frequency of sexual activity (50.7%), desire disorders (42.9%) and orgasms disorders (41.2%) revealed the highest prevalence ( Table 2) .
Impact of menopausal status on FSD
The prevalence of FSD in premenopausal women ranged from 4.8% (low satisfaction) to 38.5% (desire disorder). All aspects of FSD revealed a significant rise in postmenopausal women ( Table 1 ). The most pronounced rise was noticed for low satisfaction (4.8-14.2% ( þ 195%) (Po0.01)), the lowest rise for desire disorder (38.5-42.9% ( þ 11%) (Po0.05)) ( Table 2 ).
Impact of MS on FSD
In the premenopausal cohort, impaired desire increased from 32.1% in those with no MS to 58.8% in those with MS ( þ 83%, P ¼ 0.03) ( Table 2 ). This corresponds to an age-adjusted odds ratio (OR) of 3.3 (95% CI: 1.5-7.3). In postmenopausal women, the presence of MS had no significant impact on the prevalence of all tested aspects of FSD (Table 2 ). Both analyses were carried out after correction for age. It has to be mentioned that we observed a consistent trend including all FSDdomains independently of the menopause status with a higher prevalence of sexual disorders in women with a MS compared participants with no MS. 
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Discussion
FSD is a highly prevalent disorder with a significant impact on quality of life. Representative US prevalence data yielded that 43% of women are affected by any form of FSD. 1 In our previous study of 703 women aged 20-80 years, prevalence of major aspects of FSD ranged between 22% for desire disorder and 39% for orgasm disorder. 4 In contrast to the high prevalence of FSD, little is known regarding underlying structural and functional details of the female sexual organs.
The most important risk factor for FSD is age. In our previous study, women aged 60-69 years had a 2.8-fold higher risk for desire disorders, a 5.1-fold increased risk for arousal disorders and a 3.7-fold higher risk for orgasmic disorders compared to young controls. 4 Other important risk factors are lower urinary tract symptoms and urinary incontinence. Salonia et al.
14 reported on a high prevalence of FSD in women with lower urinary tract symptoms and urinary incontinence suggesting that assessment of FSD is warranted in these women. Geiss et al. 15 reported on a high prevalence of FSD in gynaecologic and urogynaecologic patients.
Recently, Esposito et al. assessed the prevalence of FSD in 120 premenopausal women with MS from their endocrinologic outpatient clinic and compared these data to a control group of 80 premenopausal women without MS (matched for age and body mass index). The MS group had a reduced Female Sexual Function Index score (23.2 vs 30.1; Po0.001), a reduced satisfaction rate and significantly lower arousal, orgasm and lubrication scores. Furthermore, there was an inverse relation between C-reactive protein (CRP) levels and the Female Sexual Function Index score (r ¼ À0.32, P ¼ 0.02). 10 The relevance of this topic is underscored by the fact that MS is one of the major health issues in western countries with prevalence rates about 30%, which are projected to increase steadily in the next decades. 16 We found a significantly increased proportion of reduced desire with an OR of 3.3 (95% CI: 1.5-7.3; P ¼ 0.03). In contrast, disorders of arousal, pain and orgasm and reduced frequency, importance and satisfaction were not correlated to the MS in this cohort. In postmenopausal cohort, none of the investigated aspects of FSD was related to the MS (Po0.05). From the pathophysiological standpoint, an impact of the MS would have been expected on arousal function or pain disorder rather than on libido.
Remarkable in both cohorts was the fact, that all tested domains of FSD showed a higher proportion in participants with an existing MS. This trend was stronger in the postmenopausal women with increased proportions of FSD of up to 60% (arousal disorder) in those with an MS. Therefore, we have to consider the possibility that our sample size is possibly underpowered to show an independent and significant but small impact of the MS on FSD.
We interpret our results in accordance to the data from Esposito et al. 10, 19 and Esposito and Giugliano 18 revealing a correlation between FSD and the MS in premenopausal women. We identified a different aspect (desire disorder vs MS) of the highly complex phenomenon of female sexuality potentially due to different study tools (questionnaire, MS-definition) in a different culture.
In contrast to our questionnaire, which is not validated and therefore to be seen as less conclusive, Esposito applied in her population the most popular questionnaire today regarding FSD, the Female Sexual Function Index. This validated instrument consists of 19 questions including 6 domains (desire, arousal, lubrification, orgasm, satisfaction and pain). 17 Despite the concordance of most domains (desire, arousal, pain, orgasm and satisfaction) and questions (questions 1, 3, 4 and 6 in our questionnaire correspond to question numbers 1, 17, 11 and 16 in the Female Sexual Function Index) between our questionnaire and the Female Sexual Function Index, both instruments are not comparable from the scientific standpoint. Therefore, results of both studies have to be compared with caution.
With the uncertainty of possibly underpowered results and the lack of a validated questionnaire, we have to assume that in the postmenopause the MS does not play an independent role in the genesis of FSD.
Whether the correlation between MS and FSD is caused by the impact of the MS on female sexual life (impact of the MS on vascular integrity of female genital tract), an impact of FSD on MS (reduced satisfaction in sexual life may lead to lifestyle changes with increased calorie intake), or an underlying predisposing factor for both (for instance hypothyroidism) has to be investigated in future studies.
